News

The system is marketed to companies developing biopharmaceuticals including novel compounds and biosimilars with an emphasis on therapeutic monoclonal antibodies. BioFactura president and CEO Darryl Sampey said the

The double blind, placebo controlled trial will enroll 40 patients with prodromal or mild Alzheimer’s disease to measure physical changes in the brains of patients treated with PBT2

EXC 001 drug, co-developed by Excaliard and Isis Pharmaceuticals, is an antisense oligonucleotide that will hinder the process of fibrosis. As per the deal, Pfizer will provide Excaliard

ABQ Health Partners will monitor and analyze the performance of its Electronic Health Record (EHR) solution with the help of Aternity. Aternity will provide FPI Platform, transforming desktop

Through the initiative, development of a screening program to test tumours for major genetic changes will occur. In addition, it will aid in genetic testing of both patients

MANF is a protein that corrects protein misfolding, which is the primary cause of apoptosis (cell death). Under the collaboration, Amarantus will utilize its expertise in Central Nervous

BL-1020 is a oral, GABA-enhanced antipsychotic drug candidate used for the treatment of schizophrenia. The double-blinded, randomized and positive-controlled study will enroll up to 450 patients who are

The entitled patent owned by Hoffman-La Roche’s (Roche) was licensed to Amgen upon a one-time payment and received an exclusive, fully paid-up license to the application which issued

As per the deal, Harborview Medical Center will be provided with Daxor’s Blood Volume Analyzer-100 (BVA-100), which is used for semi-automated measurement of total blood volume, red blood